16-18 July 2018 | Boston


Day One
Wednesday July 19, 2017

Day Two
Thursday July 20, 2017

Registration & Coffee

Chair’s Opening Remarks

Taking Learnings from the Clinic to Advance Preclinical Models & Translational Decision Making

Developing Checkpoint Target Humanized Models For Preclinical Efficacy Assessment


  • Lack of animal models for efficacy evaluation of human therapeutic antibodies for cancer immunotherapies
  • HuGEMM models, expressing chimeric checkpoint targets with human extracellular domains, allow the evaluation of specific human biological therapies in vivo

Patient Derived Xenografts: a platform for Personalized Care of Pancreatic Cancer

  • Jason Fleming Chairman of Gastrointestinal Oncology, Moffitt Cancer Center


  • Bridging the model to human gap through effective and predictive biomarker strategy
  • Improving characterization of preclinical models
  • Ensuring more robust and rigorous translational research that ultimately help shorten development timelines

An Expansion of IO Targets & Combinations in Humanized NSG Mice

  • Rick Huntress Director of Business Development, Clinical & In Vivo Services, The Jackson Laboratory


  • An expanding repertoire of IO drugs have been validated in CD34+ engrafted mouse model systems setting the stage for preclinical assessment of novel combinations

Speed Networking Session

Morning Refreshments

Chair: Leigh Ellis, Member of Faculty, Department of Oncologic Pathology, Dana-Farber Cancer Institute

In Vivo Model Advancements: Syngeneic Models

11.40 Identification of Novel Immune Regulators of Tumor Growth Using High-Throughput Screening In Vivo

  • We have generated a comprehensive library of substantially all human extracellular proteins including secreted proteins and the extracellular domains of membrane-bound proteins in soluble form
  • A portion of this library called the immunome contains >700 proteins with structural features characteristic of immuneactivators and checkpoints
  • The immunome library was screened in four syngeneic mouse tumor models in vivo using RIPPSSM (Rapid In vivo Protein Production System)
  • Several hits were identified and CD80-Fc was prioritized for therapeutic development based on relative efficacy and tumor immune cell profiles

Tom Brennan, Vice President, Pharmacology & Bioanalytics, FivePrime Therapeutics

12.10 Preclinical Mouse Models of Cancer Via Transposon- Mediated Mutagenesis or Gene Transfer

  • The development of the Sleeping Beauty (SB) transposon for forward genetic screens in mice: Immunoproficient, autochthonous models of cancer with clinically relevant genetic and biologic features
  • SB screens for sarcoma and mammary cancer: Identification of drivers of specific tumor biology
  • Using transposon-mediated gene delivery and CRISPR/Cas9 to model cancer in living mice
  • Porcine models of cancer

David Largaespada, American Cancer Society Research Professor, Department of Pediatrics, Masonic Cancer Center, University of Minnesota

12.40 Networking Lunch

In Vivo Model Advancements: PDX Models

14.00 Establishment & Use of a Panel of AML PDX Models to Evaluate the Efficacy of a CD33 ADC

  • Standard-of-care treatment from the perspective of response rates in the clinic and response rates in PDX
  • Evaluating response of PDX to standard-of-care treatment to validate this hypothesis and to identify dosages and schedules that can be used to identify sensitive and resistant PDX models

Edward Rosfjord, Senior Principal Scientist, Pfizer

14.30 Highly Characterized Patient-derived Xenograft Collections for Preclinical Studies

  • Use of highly characterized PDX models allow efficient preclinical drug screening
  • Ex vivo proliferation studies using PDX models mirrors in vivo studies

Jochen Hartner, Scientific Liaison; Field Application Leader, Horizon Discovery

15.00 Vascular Phenotyping in PDX models using Multimodal Imaging

  • Multimodal imaging of PDX models
  • Translational relevance of PDX models of head and neck cancer
  • Imaging-guided preclinical trials of vascular targeted therapies

Mukund Seshadri, Professor of Oncology, Departments of Pharmacology & Therapeutics, Oral Medicine/Head & Neck Surgery, Roswell Park Cancer Institute– In collaboration with Fujifilm Visualsonics

This session will finish at 15.15

Chair: Christopher Murriel, Senior Scientist II, OncoMed Pharmaceuticals

Enhancing the Use of Humanized Mice Models in Preclinical Studies

11.40 Addressing the Latest Advancements in the Development of Routine Humanized Mice for Immunotherapies

  • Discussing the latest developments in humanized mice modeling
  • Presenting data from studies utilizing humanized mice for IO therapeutic development

Nicole Walsh, Post-doctoral Associate, Molecular Medicine, University of Massachusetts Medical School

12.10 Humanized Mouse Models for Drug Discovery Research

  • Utilization of human cancer cell lines to model different aspects of human cancers
  • Discussing the relevance of humanized mouse cell subset profiles and how they compared to ex vivo human tumors and syngeneic models
  • Leveraging humanized systems for clinical translation, combination therapies, and biomarker development

Barbara Joyce-Shaikh, Associate Principal Scientist, Merck

12.40 Focal Radiation in Combination with Chemotherapy & Immunotherapy

  • Uses of focal radiation in preclinical oncology models
  • Combining focal radiation with chemotherapy in a human triple negative breast cancer model
  • Focal radiation in combination with immuno-therapy in a syngeneic murine glioblastoma model

Maryland Franklin, Vice President, Scientific Development, MI Bioresearch


12.55 Networking Lunch

Harnessing Ex Vivo Assays for the Development of Cell Therapies

14.00 Developing Ex Vivo Preclinical Models to Enhance Translation from In Vitro to In Vivo for Cell Therapies

  • What models are being utilized to predict efficacy of engineered T-cell therapies?
  • Addressing the limitations in current models and how the industry are optimizing preclinical strategies for CAR-T cell therapies

Gregor Adams, Principal Scientist, Kite Pharma Inc

14.30 Preclinical Modeling of Chimeric Antigen Receptor T Cell Therapy and Combination Immunotherapy

  • Discussing preclinical modeling in CAR-T cell therapy
  • Addressing how preclinical modeling can be used for the evaluation of CAR-T cell toxicities
  • Presenting strategies for the development of combination immunotherapy

Saad Kenderian, Assistant Professor of Medicine & Oncology, Mayo Clinic

15.00 Exploring Tumor Microenvironment Using Immuno-PET as a Predictive Tool

  • The effectiveness of immunotherapies is a direct result of changes they evoke in the tumor microenvironment
  • Identifying reproducible patterns in responders and nonresponders is key to explaining the failure or success of a therapy
  • Using immunoPET to explore dynamics of immune infiltrates in response to therapy

Mohammad Rashidian, Research Fellow, Boston Children Hospital, Harvard Medical School

Afternoon Refreshments & Poster Session

Tumor Models Interactive Roundtable Discussions


In this 1 hour session, you will have the opportunity to catch up on the latest advancements within the field and learn from your fellow colleagues in this interactive format. The topics that will be discussed are the following: 

  1. Developing predictive humanized mice models for cancer immunotherapies
  2. What benefits can organoid cultures bring to preclinical studies?
  3. Fundamental preclinical experimental design: Setting up for clinical success
  4. Using preclinical models to optimize the predictability of novel combination therapies

Close of Day 1

Networking Drinks Reception- Hosted By Crown Bioscience